Novo Nordisk A/S (NVO) — Quality & forensics

As of 2026-08-06 — refreshed nightly. Closelook readings from an investment research diary, not ratings or advice.

The Closelook module scores

54 /100 composite · 7 modules · general weight set

Valuation 84
Quality 85
Growth 30
Balance sheet 36
Cash quality 31
Capital allocation 68
Momentum 34

Scores are computed nightly across the coverage universe and read relative to it — the methodology lives in the company-scoring explainer.

Financial forensics — the academic screens

2.09 Altman Z-Score

Sits in the grey zone (1.81–2.99). The Z-Score estimates financial-distress risk from five balance-sheet and earnings ratios.

5/9 Piotroski F-Score

Nine binary fundamental-strength checks across profitability, leverage and operating efficiency.

-2.71 Beneish M-Score

Screens reported earnings for statistical manipulation patterns — below the −1.78 manipulation-risk threshold. A screen, not an accusation.

Continue: the NVO chart & overview

FAQ · from the current data · as of 2026-08-06

Quick answers

What is Novo Nordisk A/S's Closelook quality reading?

The composite reads 54/100 across 7 modules, as of 2026-08-06: valuation 84, quality 85, growth 30, balance sheet 36, cash quality 31, capital allocation 68, momentum 34. Closelook scores are research diary readings, not ratings or investment advice.

What is Novo Nordisk A/S's Altman Z-Score?

2.09, which sits in the grey zone (1.81–2.99) as of 2026-08-06. The Altman Z-Score estimates financial distress risk from five balance-sheet and earnings ratios.

What is Novo Nordisk A/S's Piotroski F-Score?

5 of 9, as of 2026-08-06. The F-Score counts nine binary fundamental-strength signals across profitability, leverage and operating efficiency.

What does Novo Nordisk A/S's Beneish M-Score indicate?

-2.71 — below the −1.78 manipulation-risk threshold, as of 2026-08-06. The M-Score screens reported earnings for statistical manipulation patterns; it is a screen, not an accusation.